Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
PI3Kδ inhibitor
DRUG CLASS:
PI3Kδ inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
copanlisib (32)
idelalisib (29)
duvelisib (26)
umbralisib (8)
INCB50465 (6)
RP6530 (6)
AZD8835 (1)
BR101801 (1)
CB-006-3 (1)
linperlisib (1)
ACP-319 (0)
BGB-10188 (0)
CVL237 (0)
HSB-510 (0)
SL-901 (0)
TQ-B3525 (0)
ZX-101A (0)
GS-9820 (0)
HMPL-689 (0)
SHC014748M (0)
INCB040093 (0)
IOA-244 (0)
ME-401 (0)
copanlisib (32)
idelalisib (29)
duvelisib (26)
umbralisib (8)
INCB50465 (6)
RP6530 (6)
AZD8835 (1)
BR101801 (1)
CB-006-3 (1)
linperlisib (1)
ACP-319 (0)
BGB-10188 (0)
CVL237 (0)
HSB-510 (0)
SL-901 (0)
TQ-B3525 (0)
ZX-101A (0)
GS-9820 (0)
HMPL-689 (0)
SHC014748M (0)
INCB040093 (0)
IOA-244 (0)
ME-401 (0)
›
Associations
(111)
News
Trials
Search handles
@DrRaulCordoba
@majorajay
Search handles
@DrRaulCordoba
@majorajay
Filter by
Latest
10ms
Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/v5J1uSXhsl (@OncLive)
10 months ago
Clinical
|
Copiktra (duvelisib)
10ms
Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/TJCxD8CBUh (@OncLive)
10 months ago
Clinical
|
Copiktra (duvelisib)
11ms
Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/vb4qA0I7UF (@OncLive)
11 months ago
Copiktra (duvelisib)
11ms
Phase 2 data of duvelisib in R/R PTCL with 50% ORR, but quite toxic with one-third cutaneous reactions and diarrhea (PROs would be helpful here) and 3 grade 5 AEs. Discontinuation d/t LFTs relatively common. #lymsm #17ICML (@majorajay)
11 months ago
P2 data
|
Copiktra (duvelisib)
11ms
True! The rapidity of progression at true BL relapse is super challenging to overcome. The BL that allows for CAR-T is inherently good risk or perhaps more HGBL or BL-like. @RoschewskiMD @NCICCR_Lymphoma has a trial of Copanlisib+EPOCH-R in R/R BL which we worked on. (@Chauhan_AF)
11 months ago
Aliqopa (copanlisib)
12ms
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study: https://t.co/0koLCSUxr5 by @jasonlukemd , Dr. Patricia M LoRusso @GarridoLagunaMD @ANaingMD et al. (@LabNaing)
12 months ago
Clinical • Combination therapy • Metastases
|
epacadostat (INCB024360) • parsaclisib (INCB50465) • itacitinib (INCB039110)
2years
Duvelisib just got approved for R/R FL in China, such an impressive difference vs. the Western (Dynamo) study!! Is it not only cancer biology, but the strategy at play here?! In fact, so impressive results, PD-1 combo in multiple solid tumors initiated! https://t.co/9dvBX4LNIW (@CrozrX)
2 years ago
PD-1 (Programmed cell death 1)
|
Copiktra (duvelisib)
almost3years
Recap of our session on "Updates in CLL": we were joined by Dr. Ryan Flynn, of @RigelPharma providing an overview of "TAVALISSE", the First Agent to Target Spleen Tyrosine Kinase (SYK) in Chronic ITP and @DeepJagMD of @CleClinicMD shedding light on Zandelisib in #BiotechShowcase (@OMIonc)
almost 3 years ago
SYK (Spleen tyrosine kinase)
|
Tavalisse (fostamatinib) • zandelisib (ME-401)
over3years
Dual Inhibition of PI3KDelta/Gamma during Manufacturing Reprograms Metabolism of CAR T Cells to Enhance Expansion and Cytotoxicity Against CLL by Dr Christopher Ronald Funk @WinshipAtEmory #ASH20 #ASHRM @Mohty_EBMT #ASHfromHome (@razan_mohty)
over 3 years ago
CAR T-Cell Therapy
|
PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
over4years
Our @naborala shares details of an MD Anderson-led study exploring the use of small molecule drug ONC201 in combination with CDK 4/6 and MEK inhibitors in triple-negative #breastcancer. #SABCS19 #endcancer (@MDAndersonNews)
over 4 years ago
Combination therapy
|
CDK4 (Cyclin-dependent kinase 4)
|
dordaviprone (ONC201)
over6years
Dual PI3K-δ,γ inhibitor duvelisib reduces immunosuppressive Tregs and myeloid cells enhancing efficacy of checkpoint and co-stimulatory antibodies in a B cell #lymphoma model @ASCO @sitcancer #ImmunoOnc #lymsm https://t.co/KtQ9IyOQuG (@DrRaulCordoba)
over 6 years ago
Clinical • Preclinical
|
Copiktra (duvelisib)
over6years
"ICYMI: @JCO study shows #copanlisib induces rapid, durable responses for advanced #Lymphoma @Bayer @LMU_Muenchen https://t.co/o4HmI7Rpy4" (@HemOncToday)
over 6 years ago
Aliqopa (copanlisib)
over6years
".@JCO study shows #copanlisib induces rapid, durable responses for advanced #Lymphoma @Bayer @LMU_Muenchen https://t.co/GxdsT81ZPe" (@GoHealio)
over 6 years ago
Aliqopa (copanlisib)
over6years
"Bayer gains first Aliqopa approval in follicular lymphoma @Bayer https://t.co/E06Sz3fz0S" (@HealthBizBlog)
over 6 years ago
Aliqopa (copanlisib)
over6years
"Bayer boosted as #FDA OKs its PI3K drug Aliqopa for relapsed follicular #lymphoma patients https://t.co/UVzecHPqTd #biopharma #pharma" (@endpts)
over 6 years ago
Clinical
|
Aliqopa (copanlisib)
over6years
"@Bayer gears up to take on @Gilead in #lymphoma with #Aliqopa green light https://t.co/0fWVGf2Pnf … #bigpharma #bloodcancerawarenessmon" (@PharmaCentra)
over 6 years ago
Aliqopa (copanlisib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login